A Phase I Study Using Most Closely HLA-matched Cytomegalovirus-specific T Lymphocytes for the Treatment of Cytomegalovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-C)

Trial Profile

A Phase I Study Using Most Closely HLA-matched Cytomegalovirus-specific T Lymphocytes for the Treatment of Cytomegalovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-C)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Cytomegalovirus specific T cells ViraCyte (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors ViraCyte
  • Most Recent Events

    • 11 Jul 2017 Results published in a ViraCyte media release.
    • 11 Jul 2017 Status changed from recruiting to completed according to a ViraCyte media release.
    • 11 Jan 2017 Company plans to complete this trial in early 2017, as reported by a ViraCyte media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top